

CLINICAL LEADERSHIP EXECUTIVE OUTBRIEF	
Date of meeting	22nd December 2020
Attendees	Group Triumvirates (Group Directors, Group Directors of Nursing and Group Directors of Operations), Director of Therapies and Executive Directors.
Apologies	Toby Lewis, Liam Kennedy, Bethan Downing, Frieza Mahmood
Key points of discussion relevant to the Board	<ul style="list-style-type: none"> • Changing situation related to covid infection impact on the Trust and progress in development of vaccination delivery. • Quality and Safety metrics that will align to Trust Strategic Objectives discussed with group leaders with plan to review further and develop a scorecard to reflect progress against the objectives. • Single quality improvement approach reviewed (QSIR) and accepted for approach to be used by the Trust for all QI work. Training package already in place • Change in car park fees from April 2021 discussed with more info on comparison with other Trusts, when last increase occurred and output from JLNCC.
Positive highlights of note	<ul style="list-style-type: none"> • Discharge to assess model and positive impact that this will have. Funding requirement to be reviewed at Joint overview committee and with better care fund as opportunities.
Matters of concern or key risks to escalate to the Board	<ul style="list-style-type: none"> • COVID risks to be reviewed and updated with new risks added as needed
Matters presented for information or noting	<ul style="list-style-type: none"> • N/A
Decisions made	<ul style="list-style-type: none"> • QSIR supported for QI methodology

David Carruthers, Acting Chief Executive
Acting Chair of the Clinical Leadership Executive
For the meeting of the Trust Board scheduled for 7th January 2020